August 22, 2012 08:05 ET

Equity Research on Mylan Inc. and Watson Pharmaceuticals Inc. - Profits and Lawsuits for Generic Drug Makers

NEW YORK, NY--(Marketwire - Aug 22, 2012) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drugs - Generic industry and are offering free analytical research on Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI). Register with us now to have free access to these research reports. Simply click on the link below.

For companies in the generic drug industry, lawsuits are part of the operating environment and can mean the difference between soaring profits and disappointing losses. Several companies including Watson Pharmaceuticals Inc. are currently involved in litigation and it will be interesting to see how things settle moving forward. Watson Pharmaceuticals Inc. report is accessible for free by registering today at is the Ultimate Trading Environment for investors. If you are considering owning Mylan Inc. and Watson Pharmaceuticals Inc. then you should sign up for a free membership and our complimentary reports today. Over the last 5 years our returns outpaced any of the major indexes. Sign up today by clicking on the link below to find out what you are missing.

The industry, which features companies such as Mylan Inc., has been benefitting from a number of high profile patent expirations as of late, and individual company earnings are reflective of this. Get your free reports on Mylan Inc. and Watson Pharmaceuticals Inc. at There is no commitment to join.

The industry is also well positioned to take advantage of cash-conscious consumers who are currently looking for ways to cut down on expenses. In its most recent quarter, Mylan saw adjusted diluted earnings per share grow by 15% year-over-year, and was also able to increase revenues by 7%. Mylan also recently stated that it is now selling a generic version of Takeda Pharmaceuticals' Actos® Tablets and Actoplus Met® Tablets, used in improving glycemic control in adults that have type 2 diabetes mellitus. Mylan Inc. report is accessible for free by registering today at

The two Drugs - Generic stocks research reports are available for free by signing up now on the link below.

Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information